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ha human, the gone coding for apolipoprotein A-I (apo A-I), a protein of the plasma lipid transport system, is expressed only in the liver and the 
intestine, A naturally occurring A to G substitution i the promoter at position -78 was shown to be associated with high density lip0proteins 
(HDL) in females. We have studied the effect of this mutation on promoter activity using various lengths of protnoter sequences and the CAT 
reporter $ene system, Transient expression studies after introduction ofthese constructs into Hop 3B cells r~vc.aled that in the region spanning -330 
to + I of the promoter an A to G substitution i creases the activity approximately twofold, On the other hand, when further upstream r~gion (-  1469 
to +397) is also included, th~ promoter activity seems comparable inboth alleles, Our results how how minimal sequence variations can affect 
the in vitro a~mlysis or'promoter activity. 
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1. INTRODUCTION 
In mammals apolipoprotein A.I (apo A-I) is a single 
polypeptide chain composed of 243 amino acids. It 
plays a central structural and metabolic role in high 
density lipoproteins (HDL). In fact apo A-I is the major 
protein of HDL and a cofactor for lecithin-cholesterol 
aeyltransferase [1]. In most mammalian species the apo 
A-I synthesis has been demonstrated predominantly in 
the liver and intestine [2,5]. Small quantities of apo A-I 
mRNA have also been found in a variety of mammalian 
tissues [3,4]. Apo A-I promotes cholesterol efflux from 
cultured cells [6,7], a process called reverse cholesterol 
transport. This process is mediated by interaction of 
HDL with its receptor [8] and may protect against ath- 
eroselerosis. 
The genes coding for apo A-I and for two other apol- 
ipoproteins Cl I I  and AIV are closely linked and tan- 
demly organized within a 15-kb DNA segment [9]. In 
certain patients with premature coronar} ~ artery disease, 
it has been shown that di.~ruptioa of' the structure of this 
gone cluster esults in altered expression of the apo A-I 
and apo CIII genes leading to combined apo A-I, apo 
CIII and HDL deficiency, the major risk factor for 
accelerated atheroselerosis in these patients [10]. 
The cis- and trans.acting elements involved in apo 
A-I gone transcription and their ~ombinationat modula- 
tion have been extensively studied [11,12]. The DNA 
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segment located between ucleotides -256 to -41 le- 
gion upstream from the transcription start site (+1) of 
the human apo A-I gene contains regulatory elements 
which are necessary and sufficient for expression in 
hepatoma (Hop G2) cells [13]. In the human population 
we have already reported the distribution of a polymor- 
phism due to an adenine (A) to guanine (G) transition, 
78 bp upstream from the transcription start site of the 
apo A-I gone [14]. The DNA region surrounding the 
polymorphism is a 51-bp fragment that is G-C rich and 
contains an inverted repeat composed of two I4/15 bp 
elements [14]. When G is present instead of A at posi- 
tion -78, the homology and self complementarity of the 
inverted repeats is disrupted. Both direct and inverted 
repeat sequences within the 5"-flanking regions are in- 
volved in the regulation of gene expression [15,16,22]. 
We have also reported that the A allele is associated 
with high HDL-C and apo AI levels in women but not 
in men [14]. In the present manuscript we describe x- 
periments showing that the sequences flanking the mu- 
tation are determinant for the differential promoter ac- 
tivity in vitroof the apo A-I-G and apo A-I-A alleles. 
2. MATERIALS AND METHODS 
2.1, Cell ctdture 
Hop 3B (human hepatoma) cells were grown in Dulbeceo's modified 
Eagle's medium containing 10% t~tal calf serum, 50/.tg/ml gentamycin 
and 2 mM $1utamine. 
2.2, ~bnstruction oJ' C',,1 "l'Jkaiotl genes 
For the construction of pTZI90CAT, the CAT gone was eaclsed 
from pSV2CAT by digesting with Hindlli and Bt~,HI enzymes arid 
98 Published by E/set,let Scier.~e Publishera' lt. It. 
Volume 304, number I FEBS LETTERS June 1992 
cloned into the respective site of pTZ19 (Pharmacia). The A and G 
variants of the apo A-f promoter were obtained by PCR amplification 
of the genomic DNA. 
Primer PAL I : 5’.TTAAGCTTCTTCTAGAACACAATGGCAA- 
CT3’ (contains Hi!ldIII and X~PI sites) 5’ end at -330 bp, 
Primer RAI.1: S’TTAAGCTTCTAAGCAGCCAGCTCTTGCA3’ 
(contains a Hltldlll site) 5’ end at + I, 
The 33tLbp fragment obtained was cloned at the respective site in 
pTZl90 CAT (Fig. I). The only mutation was confirmed by sequence 
analysis and the orientation of the insert was confirmed by restriction 
enzyme analysis. 
For the larger fragment of the apo A-I promoter, a genomic sub- 
clone [IS,lS] was used which was digested with Hi/tdIII and cloned 
into pTZI9OCAT. These (-1469 ALA CAT, - 1469 A1.G CAT) con- 
tain the promoter egion - 1469 to +397 (exon 1, intron 1, coon 2 and 
122 nucleotides of intron 2) in the samedircction oftranscription with 
the CAT gene (Fig. I) [13], These two constructs were digested by 
4naI (site at -250) and the fragments were exchanged to generate the 
two new construcls (-1469 AI. AG CAT and -14G9 ALGA CAT). 
This manipulation was necessary to eliminate any other sequence 
difference between the A and G alleles. The DNA used for lransfection 
was purified by CsCl gradient centrifugation [ 191. 
The day before transfection, Hep 3B cells were seeded al a density 
of 2x10’ cells/60 mm dish and were grown in 5 ml of the medium at 
37°C and 5% CO, for 20 h. SubscquenUy, the cclis were fed with fresh 
medium. ar,d 4 h later the DNA (ISpy, calcium phosphate co-prccip 
itate) was added. At I5 to 18 h later the cells were washed once with 
PBB and supplcmentcd with fresh medium. Forty-eight hours later, 
the cells were collected by &raping and used for the preparation of 
protein extracts 1191. 
Cell protein extracts were made by sonicating washed, pelleted cells 
in 200~1 of0.25 M Tris-HCI. For each ttansfection, halfof the extract 
was incubated for 10 min at 65°C to inactivate ndogenous deacc- 
tylascs and after centrifyation was used for CATassay [16]. The CAT 
assay mixture contained 0.25 yCi of [W]chloramphenicol, 250 PM 
Tris-HCI (pH 7.8). 0,s mM acetyl-CoA and 80.~1 of extract in a final 
volume of I60 ~1. The reaction mixture was incubated at 37°C for 2 
h and extracted with I ml of ethyl acetate. The ethyl acetate was 
evaporated and the pellets redissolved in 25 yl of ethyl acetate and 
analyzed by silica gel TLC (DC-Ptastikfolien-Merck) in chloroform/ 
methanol (95:s) for 30 min. The CAT activity was quantitated by 
cutting out the rcspectivc spots and counting. The CAT activity was 
normalized for efficiency of transfeclion, which was determined by 
slot-blot analysis of the cell lysates [?O]. The protein concentration of 
the extract was determined using the Bio-Rad protein assay kit. 
3. RESULTS AND DISCUSSION 
The -330 to -1-l A1.A CAT and A1.G CAT plasmids 
were constructed by PCR amplification of genomic 
DNA as already described. It was also confirmed by 
direct sequencing that the A to G substitution at -78 
was the only difference between the two constructs. The 
CAT activity level obtained after transfection of these 
revealed a reproducibly significant difference between 
the activity of the two promoters, The CAT activity was 
determined and normalized for the DNA uptake (by 
slot-blot hybridization) and for the protein content of 
the extract. Both DNA uptake and protein content did 
not show significant variations from experiment to ex- 
periment. It was observed that tine construct with G at 
position -78 gives a twofold higher promoter activity 
(Fig. 2). These results are in contrast o the observation 
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Fig. I. Structure of the Apo A-I promoter - CAT fusion genes, The 
upper two are constructed by amplificalion of genomic DNA and the 
lower two arc subclones of genomic lones. 
in vivo, where we found an association of the A allele 
with high plasma HDL-cholesterol level [14]. ‘The nucle- 
otides -256 to -41 have been previously shown to be 
an essential &-acting element for the expression of apo 
A-l in hepatoma cells [ 131. Particularly the position -78 
is located immediately 3’ of the region B that has been 
shown to be protected (- 128 to -77) by nuclear extracts 
and 5’ of a hypersensitive site [21]. The transcription 
factor interacting with these sequences has not yet been 
identified [21]. 
To further explore the interactions involved in the 
modulation of transcription with both the ‘A’ and ‘G’ 
promoter sequences two constructs were made identical 
to those previously described [13]. These constructs con- 
tain longer upstream promoter region (-1469) and ex- 
tend at 3’ end into exon I, intron I, exon II and 122 
nucleotides of intron II of apo A-I fused in the same 
transcriptional orientation with the bacterial CAT gene 
(-1469 AI. A CAT and -1469 AI. G. CAT). An ideuti- 
cal construct was previously shown to give reliable CAT 
activity notwithstanding the anomalous inclusion of 
apo A-I intron sequences [13]. The sequence analysis of 
-256 to -41 region in these constructs howed them to 
be identical except for the A to G substitution. No 
complete sequence information was available for the 
region -1469 to -250 so to rule out any effect of se- 
quence variations in further upstream region of the pro- 
moter (-1469 to -250) on this portion (-250 to t397) 
two new constructs were made by exchanging the S/naI 
fragment comprising the SnraI site at -250 in the apo 
A-I gene and the S~,tal site in the polylinker generating 
the constructs (- 1469 Al. AG CAT and - 1.169 AI. GA 
CAT). These constructs were used for transient gene 
cxprcssion and the CAT activity of the protein extract 
of these cells was measured. The results showed that 
-1469 AI. A CAT is a slightly stronger promoter than 
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Fig. 2. CAT assay after transfection in Hep 3 B cells. Panel A: autoradiogram of the CAT assay. Lane 1 is the acetylation control using E. coii 
CAT enzyme. The constrticts used are shown at the bottom of the autoradiogram. Panel B: schematic represemation ofCAT assays of panel A. 
CAT activities are presented in relative values assuming the CAT activity from -330 AMCAT to be 100. The difference between the promorcr 
activity of -330 G and -330 A alleles is significant, while that between -1463 G and -1469 A alleles is not.The results hown are averages of at 
least three independent iransfections. 
its G counterpart (72.4% vs. 62% of awtylation). Al- tion factors identified [21,23]. The deletion studies have 
most identical results were obtained when the two other shown previously [13] that the apo A? promoter activ- 
constructs made after exchanging the SntaI fragment ities of constructs including -250 and -2500 flanking 
were used (Fig. 2, Panel B). The exchange of fragment regions were comparable. However these studies have 
abolished polymorphic differences but for the A to G been performed with one version of the apo A-I gene. 
substitution, while the difference between -330 ‘A’ and This result would have been different if the A allele was 
-330 ‘G’ alleles are certain, while the slightly higher used instead of G allele in the study. In fact we have 
-1469 A promoter activity is not significant [14]. De- shown here that the ‘A’ -330 construct has considerably 
tailed analysis of the nucleotide sequences involved in lower activity than its ‘G’ counterpart. In the human 
the Apolipoprotein A-I gene transcription has already population there are naturally occurring variants which 
been carried out [13,21-231 and some of the transcrip- may have a moderate influence on the rate of transcrip- 
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tion and may in part explain the wide range of HDL  and 
apo A-I levels found in the populat ion including our 
previous observation of high HDL in females carrying 
the "A' allele [14]. We have shown in this study that a 
sequence variation may in vitro have a paradoxical ef- 
fect depending on how much flanking gene sequences 
are included in the constructs. A complete picture of the 
interactions and fine modulat ion of  apo A-I  gene ex- 
pression can be obtained only f rom in vivo experiments 
using extensive 5'-flanking regions. 
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